CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 85.24% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money

Trade Rhythm Pharmaceuticals Inc - RYTM CFD

64.33
0.63%
Market Trading Hours* (UTC) Opens on Tuesday at 13:30

Mon - Fri: 13:30 - 20:00

  • Summary
  • Historical Data
Trading сonditions
Spread 0.13
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.02354 %
Charges from full value of position ($-0.24)
Trade size with leverage ~ $2,000.00
Money from leverage ~ $1,000.00

Go to platform
-0.02354%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.001318 %
Charges from full value of position ($0.01)
Trade size with leverage ~ $2,000.00
Money from leverage ~ $1,000.00

Go to platform
0.001318%
Overnight fee time 21:00 (UTC)
Min traded quantity 0.1
Currency USD
Margin 50.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 63.93
Open 63.64
1-Year Change 46.03%
Day's Range 62.96 - 64.43
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
May 2, 2025 63.93 0.08 0.13% 63.85 65.93 63.68
May 1, 2025 63.66 -0.84 -1.30% 64.50 65.46 62.95
Apr 30, 2025 65.08 1.33 2.09% 63.75 65.47 63.75
Apr 29, 2025 65.12 1.67 2.63% 63.45 65.41 63.40
Apr 28, 2025 64.27 0.42 0.66% 63.85 64.50 63.32
Apr 25, 2025 63.59 1.54 2.48% 62.05 63.86 60.95
Apr 24, 2025 62.79 2.91 4.86% 59.88 63.05 59.59
Apr 23, 2025 59.78 -0.27 -0.45% 60.05 61.53 58.93
Apr 22, 2025 59.13 -1.82 -2.99% 60.95 61.72 59.02
Apr 21, 2025 60.43 -0.47 -0.77% 60.90 62.66 60.24
Apr 17, 2025 61.62 0.67 1.10% 60.95 61.85 60.15
Apr 16, 2025 61.32 -0.09 -0.15% 61.41 61.45 59.49
Apr 15, 2025 61.98 1.87 3.11% 60.11 62.31 60.09
Apr 14, 2025 60.01 0.46 0.77% 59.55 60.30 58.10
Apr 11, 2025 59.47 1.83 3.17% 57.64 60.00 55.90
Apr 10, 2025 57.72 -0.48 -0.82% 58.20 58.83 54.73
Apr 9, 2025 60.17 4.22 7.54% 55.95 61.28 49.82
Apr 8, 2025 57.67 0.48 0.84% 57.19 62.87 56.25
Apr 7, 2025 54.92 6.87 14.30% 48.05 55.77 45.77
Apr 4, 2025 46.81 -1.78 -3.66% 48.59 48.84 46.13

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
Leverage
2:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Rhythm Pharma Company profile

About Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on developing treatment for genetic diseases of obesity, which are characterized by early-onset, severe obesity and an insatiable hunger (hyperphagia). Its lead product candidate, IMCIVREE (setmelanotide), is a potent melanocortin-4 receptor (MC4R). IMCIVREE is developed for the treatment of rare genetic diseases of obesity. It is focused on the melanocortin-4 receptor (MC4R) pathway, which is responsible for regulating weight and hunger. It targets the MC4R pathway to develop therapeutics for rare genetic diseases of obesity, including proopiomelanocortin (POMC) deficiency obesity, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl syndrome (BBS), Alstrom syndrome, POMC or LEPR heterozygous deficiency obesity, Smith-Magenis syndrome, steroid receptor coactivator 1 (SRC1) deficiency obesity, MC4R deficiency obesity and SH2B adapter protein 1 (SH2B1) deficiency obesity.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Rhythm Pharmaceuticals Inc revenues increased from $0K to $3.2M. Net loss decreased 48% to $69.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Basic Earnings per Share excluding Extraordinary Items increased from -$3.04 to -$1.40.

Industry: Bio Therapeutic Drugs

222 Berkeley Street
12th Floor Boston
BOSTON
MASSACHUSETTS 02116
US

People also watch

ETH/USD

1,805.09 Price
-1.820% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 1.75

XRP/USD

2.13 Price
-2.900% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 0.01061

BTC/USD

94,059.85 Price
-1.890% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 50.00

US100

19,931.20 Price
-0.950% 1D Chg, %
Long position overnight fee -0.0235%
Short position overnight fee 0.0013%
Overnight fee time 21:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 720,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading